According to regulatory filings released Thursday, operating profit climbed 23 percent from a year earlier to 586.4 billion won.
The robust growth came despite the company's first-ever full walkout, a five-day strike from May 1 that halted some production batches after a parts-handling unit downed tools days earlier, choking the supply of raw materials.
Samsung Biologics had estimated related losses at about 150 billion won.
Shrugging off that disruption, the company said it expects to reach the upper end of its full-year 2026 revenue growth guidance of 15 percent to 20 percent, citing an expanding contribution from the fifth plant and the Rockville facility alongside the currency tailwind.
The firm said it would open a European sales office in the Netherlands during the third quarter, adding to bases in New Jersey and Tokyo, and pointed to its acquisition of peptide specialist PolyPeptide Group and a secured site for a third bio campus as it pushes beyond antibody drugs into mRNA and antibody-drug conjugates.
Copyright ⓒ Aju Press All rights reserved.
